Reversal of iron‐induced dilated cardiomyopathy during therapy with deferasirox in beta‐thalassemia

O. Trad,M. Hamdan,A. Jamil,M. Khanani,M. K. Ishaqi,Aisha Shamsi,Mohamed Hayek
DOI: https://doi.org/10.1002/pbc.21795
2009-03-01
Pediatric Blood & Cancer
Abstract:A 15‐year‐old male with β‐thalassemia major developed dilated cardiomyopathy secondary to iron‐overload (Z‐scores of left ventricle (LV) dimensions >3, ejection fraction (EF) 33%). Treatment with deferoxamine was unsuccessful, presumably due to poor compliance. After 15 months of using deferasirox (DFX), LV end‐diastolic dimension normalized (Z‐scores <2), and EF improved to 58%. We conclude that treatment with DFX resulted in a reversal of iron‐induced cardiomyopathy. Pediatr Blood Cancer 2009;52:426–428. © 2008 Wiley‐Liss, Inc.
What problem does this paper attempt to address?